Updating corneofungimetry: a bioassay exploring dermatomycoses and antifungal susceptibility.

[en] Superficial dermatomycoses are frequent conditions in humans and animals. Specific treatment modalities have been designed using a variety of different antifungal compounds. The need for antifungal susceptibility testing (AST) has been growing steadily over the last two decades due to the extending number of newer antifungal agents. Objective inter- and intraindividual comparisons of their respective efficacies are nearly impossible to perform in vivo. Currently, a series of standardized AST methods and interpretative guidelines have been designed. However, their clinical relevance for dermatomycoses is not consistent. The corneofungimetry bioassay was designed to test comparatively a series of antifungals on pathogenic fungi growing on sheets of human stratum corneum. Computerized morphometric assessments bring numerical values allowing statistical comparisons. Variants of corneofungimetry address more specific aspects related to fungal cell adhesion, fungitoxicity and lipid-dependent fungi.

Disciplines :

Dermatology

Author, co-author :

Pierard, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Franchimont, Claudine ; Université de Liège - ULiège > Dermatopathologie

Quatresooz, Pascale ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Language :

English

Title :

Updating corneofungimetry: a bioassay exploring dermatomycoses and antifungal susceptibility.

Publication date :

2010

Journal title :

Mycopathologia

ISSN :

0301-486X

eISSN :

1573-0832

Publisher :

Kluwer Academic Publishers, Netherlands

Volume :

169

Issue :

Pages :

27-35

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 11 January 2010

Statistics

Number of views

49 (5 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Odds FC, Vranckx L, Woestenborghs F. Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation. Antimicrob Agents Chemother. 1995; 39: 2051-60.
Llop C, Sala J, Riba MD, Guarro J. Antimicrobial susceptibility testing of dematiaceous filamentous fungi: effect of medium composition at different temperatures and times of reading. Mycopathologia. 1999; 148: 25-31.
Figueiredo VT, de Assis Santos D, Resende MA, Hamdan JS. Identification and in vitro antifungal susceptibility testing of 200 clinical isolates of Candida spp. responsible for fingernail infections. Mycopathologia. 2007; 164: 27-33.
Teixeira AB, Silva M, Lyra L, et al. Antifungal susceptibility and pathogenic potential of environmental isolated filamentous fungi compared with colonizing agents in immunocompromised patients. Mycopathologia. 2005; 160: 129-35.
Martinez-Rossi NM, Peres NT, Rossi A. Antifungal resistance mechanisms in dermatophytes. Mycopathologia. 2008; 166: 369-83.
Piérard GE, Vroome V, Borgers M, et al. New insights in the effects of topical ketoconazole. Curr Top Pharmacol. 2006; 10: 59-65.
Hardin TC, Najvar LK, Rizzo J, et al. Discrepancy between in vitro and in vivo antifungal activity of albendazole. J Med Vet Mycol. 1997; 35: 153-8.
Degreef H. Clinical forms of dermatophytosis (ringworm infection). Mycopathologia. 2008; 166: 257-65.
Knight AG. Culture of dermatophytes upon stratum corneum. J Invest Dermatol. 1972; 59: 427-31.
Knight AC. Human models for in vivo and in vitro assessment of topical antifungal agents. Br J Dermatol. 1973; 89: 509-14.
Faergemann J, Aly R, Maibach HI. Growth filament production of Pityrosporum orbiculare, P ovale on human stratum corneum in vitro. Acta Derm Venereol. 1983; 63: 388-92.
Faergemann J. A new model for growth and filament production of Pityrosporum ovale (orbiculare) on human stratum corneum in vitro. J Invest Dermatol. 1989; 92: 117-9.
Rurangirwa A, Piérard-Franchimont C, Piérard GE. Culture of fungi on cyanoacrylate skin surface strippings-a quantitative bioassay for evaluating antifungal drugs. Clin Exp Dermatol. 1989; 59: 425-8.
Osborne CS, Leitner I, Favre B, Ryder NS. Antifungal drug response in an in vitro model of dermatophyte nail infection. Med Mycol. 2004; 42: 159-63.
Droschner RA, Lopez-Garcia B, Massie J, et al. Innate immune defense of the nail unit by antimicrobial peptides. J Am Acad Dermatol. 2004; 50: 343-8.
Jensen JM, Pfeiffer S, Akaki T, et al. Barrier function, epidermal differentiation, and human beta-defensin 2 expression in tinea corporis. J Invest Dermatol. 2007; 127: 1720-7.
Kawai M, Yamazaki M, Tsuboi R, et al. Human beta-defensin-2, an antimicrobial peptide, was elevated in scales collected from tinea pedis patients. Int J Dermatol. 2006; 45: 1389-90.
Piérard GE, Arrese JE, Quatresooz P, Piérard-Franchimont C. Emerging antifungal agents for onychomycosis. Exp Opin Emerg Drugs. 2007; 12: 345-53.
Piérard GE, Piérard-Franchimont C, Vroome V, et al. Established and emerging oral antifungals in dermatology. In: Walters HA, Roberts MS, editors. Dermatologic, cosmeceutic cosmetic development. New York: Publ Informa Healthcare; 2008. p. 283-96.
Braff MH, Bardan A, Nizet V, Gallo RL. Cutaneous defense mechanisms by antimicrobial peptides. J Invest Dermatol. 2005; 125: 9-13.
Izadpanah A, Gallo RL. Antimicrobial peptides. J Am Acad Dermatol. 2005; 52: 381-90.
Yamasaki K, Gallo RL. Antimicrobial peptides in human skin disease. Eur J Dermatol. 2008; 18: 11-21.
Harder J, Meyer-Hoffert U, Wehkamp K, et al. Differential gene induction of human β-defensins (hBD-1, -2, -3, and -4) in keratinocytes is inhibited by retinoic acid. J Invest Dermatol. 2004; 123: 522-9.
Baroni A, Orlando M, Donnarumma G, et al. Toll-like receptor 2 (TLR2) mediates intracellular signalling in human keratinocytes in response to Malassezia furfur. Arch Dermatol Res. 2006; 297: 280-8.
Bowdish DM, Davidson DJ, Hancock RE. Immunomodulatory properties of defensins and cathelicidins. Curr Top Microbiol Immunol. 2006; 306: 27-66.
Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med. 2007; 13: 552-9.
Zheng Y, Niyonsaba F, Ushio H, et al. Cathelicidin LL-37 induces the generation of reactive oxygen species and release of human α-defensins from neutrophils. Br J Dermatol. 2007; 157: 1124-31.
Speth C, Rambach G, Würzner R, Lass-Flörl C. Complement and fungal pathogens: an update. Mycoses. 2008; 51: 477-96.
Sawaki K, Mizukawa N, Yamaai T, Fukunaga J, Sugahara T. Immunohistochemical study on expression of alpha-defensin and beta-defensin-2 in human buccal epithelia with candidiasis. Oral Dis. 2002; 8: 37-41.
Abiko Y, Jinbu Y, Noguchi T, et al. Upregulation of human beta-defensin 2 peptide expression in oral lichen planus, leukoplakia and candidiasis, an immunohistochemical study. Pathol Res Pract. 2002; 198: 537-42.
Hubert P, Herman L, Maillard C, et al. Defensins induce the recruitment of dendritic cells in cervical human papillomavirus-associated (pre)neoplastic lesions formed in vitro and transplanted in vivo. FASEB J. 2007; 21: 2765-75.
Pernet I, Reymermier C, Guezennec A, et al. An optimized method for intensive screening of molecules that stimulate β-defensins 2 or 3 (hBD2 or hBD3) expression in cultured normal human keratinocytes. Int J Cosmet Sci. 2005; 27: 161-70.
Roeder A, Kirschning CJ, Rupec RA, et al. Toll-like receptors as key mediators in innate antifungal immunity. Med Mycol. 2004; 42: 485-98.
Donnarumma G, Paoletti I, Buommino E, et al. Malassezia furfur induces the expression of β-defensins-2 in human keratinocytes in a protein kinase C-dependent manner. Arch Dermatol Res. 2004; 295: 474-81.
Quatresooz P, Piérard-Franchimont C, Arrese JE, Piérard GE. Clinicopathologic presentations of dermatomycoses in cancer patients. J Eur Acad Dermatol Venereol. 2008; 22: 407-17.
Piérard GE, Quatresooz P, Arrese JE. Spotlight on nail histomycology. Dermatol Clin. 2006; 24: 371-4.
Paquet P, Piérard-Franchimont C, Piérard GE, Quatresooz P. Skin fungal biocontamination and the skin hydrogel pad test. Arch Dermatol Res. 2008; 300: 167-71.
Piérard GE. Seborrheic dermatitis today, gone tomorrow? The link between the bioscene and treatment. Dermatology. 2003; 206: 233-40.
Piérard GE, Xhauflaire-Uhoda E, Piérard-Franchimont C. The key role of corneocytes in pityrosporoses. Dermatology. 2006; 212: 23-6.
Arrese JE, Piérard GE. Treatment failures and relapses in onychomycosis: a stubborn clinical problem. Dermatology. 2003; 207: 255-60.
Piérard GE. Spores, sporodochia and fomites in onychomycosis. Dermatology. 2006; 213: 169-72.
Piérard GE, Piérard-Franchimont C, Quatresooz P. Fungal thigmotropism in onychomycosis and in a clear hydrogel pad model. Dermatology. 2007; 215: 107-13.
National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS Document M27-A2. PA, USA, Wayne, 2002.
National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of conidium forming filamentous fungi. Approved standard M38-A. PA, USA, Wayne, 2002.
National Committee for Clinical Laboratory Standards. Methods for antifungal disk diffusion susceptibility testing of yeasts; approved guideline M44-A. Wayne, PA: National Committee for Clinical Laboratory Standards; 2004.
Swinne D, Watelle M, van der Flaes M, Nolard N. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study). Mycoses. 2004; 47: 177-83.
Carrillo-Munoz AJ, Quindos G, Ruesga M, et al. In vitro antifungal susceptibility testing of filamentous fungi with Sensititre Yeast One™. Mycoses. 2006; 49: 293-7.
Valve-Silva LA, Buchta V. Antifungal susceptibility testing by flow cytometry: is it the future? Mycoses. 2006; 49: 261-73.
Arikan S. Current status of antifungal susceptibility testing methods. Med Mycol. 2007; 45: 569-87.
Singh J, Zaman M, Gupta AK. Evaluation of microdilution and disk diffusion methods for antifungal susceptibility testing of dermatophytes. Med Mycol. 2007; 45: 595-602.
Ergin A, Arikan S. Comparison of microdilution and disc diffusion methods in assessing the in vitro activity of fluconazole and Melaleuca alternifolia (tea tree) oil against vaginal Candida isolates. J Chemother. 2002; 14: 465-72.
Whiting DA, Bisset EA. The investigation of superficial fungal infections by skin surface biopsy. Br J Dermatol. 1974; 91: 57-65.
Knudsen EA. The areal extent of dermatophyte infection. Br J Dermatol. 1975; 92: 413-6.
Piérard-Franchimont C, Piérard GE. Skin surface stripping in diagnosing and monitoring inflammatory, xerotic and neoplastic diseases. Pediatr Dermatol. 1985; 2: 180-4.
Naka W, Hanyaku H, Tajima S, et al. Application of neutral red staining for evaluation of the viability of dermatophytes and Candida in human skin scales. J Med Vet Mycol. 1994; 32: 31-5.
Piérard GE, Rurangirwa A, Piérard-Franchimont C. Bioavailability of fluconazole and ketoconazole in human stratum corneum and oral mucosa. Clin Exp Dermatol. 1991; 16: 167-71.
Aljabre SHM, Richardson MD, Scott EM, Shakland GS. Germination of Trichophyton mentagrophytes on human stratum corneum in vitro. J Med Vet Mycol. 1992; 30: 145-52.
Piérard GE, Piérard-Franchimont C, Arrese Estrada J. Comparative study of the activity and lingering effect of topical antifungals. Skin Pharmacol. 1993; 6: 208-14.
Arrese JE, Schrooten P, De Doncker P. et al. Fungal cultures on cyanoacrylate skin surface strippings as a dose-finding method for topical antifungals. A placebo-controlled study with itraconazole 0. 25% and 0. 50% cream. J Med Vet Mycol. 1995; 33: 127-30.
Arrese JE, Fogouang L, Piérard-Franchimont C, Piérard GE. Euclidean and fractal computer-assisted corneofungimetry. A comparison of 2% ketoconazole and 1% terbinafine topical formulations. Dermatology. 2002; 204: 222-7.
Piérard GE, Arrese JE, De Doncker P. Antifungal activity of itraconazole and terbinafine in human stratum corneum: a comparative study. J Am Acad Dermatol. 1995; 32: 429-35.
Piérard GE, Piérard-Franchimont C, Arrese JE. Povidone-iodine wash solutions in the prevention of superficial fungal infections: predictive evaluation using the corneofungimetry bioassay. Eur J Clin Pharmacol. 1997; 53: 101-4.
Arrese JE, De Doncker P, Odds FC, Piérard GE. Reduction in the growth of non-dermatophyte moulds by itraconazole: evaluation by corneofungimetry assay. Mycoses. 1998; 41: 461-5.
Piérard-Franchimont C, Ausma J, Wouters L, et al. Activity of the triazole antifungal R12663 as assessed by corneofungimetry. Skin Pharmacol Physiol. 2006; 19: 50-6.
Piérard-Franchimont C, Vroome V, Cauwenbergh G, Piérard GE. Corneofungimetry bioassay on Malassezia spp. under ketoconazole and desonide influences. Skin Pharmacol Physiol. 2005; 18: 98-102.
Rurangirwa A, Piérard-Franchimont C, Piérard GE. Growth of Candida albicans on the stratum corneum of diabetic and non-diabetic patients. Mycoses. 1990; 33: 253-5.
Smijs TGM, Bouwstra JA, Schuitmakers HJ, Talebi M, Pavel S. A novel ex vivo skin model to study the susceptibility of the dermatophyte Trichophyton rubrum to photodynamic treatment in different growth phases. J Antimicrob Chemother. 2007; 59: 433-40.
Dorocka-Bobkowska B, Konopka K, Düzgünes N. Influence of antifungal polyenes on the adhesion of Candida albicans and Candida glabrata to human epithelial cells in vitro. Arch Oral Biol. 2003; 48: 805-14.
He XY, Meurman JH, Kari K, et al. In vitro adhesion of Candida species to denture base materials. Mycoses. 2006; 49: 80-4.